Department of Pediatrics, Peking University First Hospital, Beijing, China.
Department of Pediatric Nephrology and Rheumatism and Immunology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Pediatr Res. 2023 Aug;94(2):747-755. doi: 10.1038/s41390-023-02542-0. Epub 2023 Mar 2.
This study investigated the association between urinary epidermal growth factor (EGF) and complete remission (CR) of proteinuria in children with IgA nephropathy (IgAN).
We included 108 patients from the Registry of IgA Nephropathy in Chinese Children. The urinary EGF at the baseline and follow-up were measured and normalized by urine creatinine (expressed as uEGF/Cr). The person-specific uEGF/Cr slopes were estimated using linear mixed-effects models for the subset of patients with longitudinal data of uEGF/Cr. Cox models were used to analyze the associations of baseline uEGF/Cr and uEGF/Cr slope with CR of proteinuria.
Patients with high baseline uEGF/Cr were more likely to achieve CR of proteinuria (adjusted HR 2.24, 95% CI: 1.05-4.79). The addition of high baseline uEGF/Cr on the traditional parameters significantly improved the model fit for predicting CR of proteinuria. In the subset of patients with longitudinal data of uEGF/Cr, high uEGF/Cr slope was associated with a higher likelihood of CR of proteinuria (adjusted HR 4.03, 95% CI: 1.02-15.88).
Urinary EGF may be a useful noninvasive biomarker for predicting and monitoring CR of proteinuria in children with IgAN.
High levels of baseline uEGF/Cr (>21.45 ng/mg) could serve as an independent predictor for CR of proteinuria. The addition of baseline uEGF/Cr on the traditional clinical pathological parameters significantly improved the fitting ability for the prediction of CR of proteinuria. Longitudinal data of uEGF/Cr were also independently associated with CR of proteinuria. Our study provides evidence that urinary EGF may be a useful noninvasive biomarker in the prediction of CR of proteinuria as well as monitoring therapeutic response, thus guiding treatment strategies in clinical practice for children with IgAN.
本研究旨在探讨 IgA 肾病(IgAN)患儿尿表皮生长因子(EGF)与蛋白尿完全缓解(CR)之间的关系。
我们纳入了中国儿童 IgA 肾病登记研究中的 108 例患者。测量并通过尿肌酐标准化基线和随访时的尿 EGF(表示为 uEGF/Cr)。对于具有 uEGF/Cr 纵向数据的患者亚组,使用线性混合效应模型估计个体特定的 uEGF/Cr 斜率。使用 Cox 模型分析基线 uEGF/Cr 和 uEGF/Cr 斜率与蛋白尿 CR 的相关性。
基线 uEGF/Cr 较高的患者更有可能实现蛋白尿 CR(调整后的 HR 2.24,95%CI:1.05-4.79)。基线 uEGF/Cr 高值联合传统参数可显著改善预测蛋白尿 CR 的模型拟合度。在具有 uEGF/Cr 纵向数据的患者亚组中,uEGF/Cr 斜率较高与蛋白尿 CR 的可能性更高相关(调整后的 HR 4.03,95%CI:1.02-15.88)。
尿 EGF 可能是预测和监测 IgAN 患儿蛋白尿 CR 的有用非侵入性生物标志物。
基线 uEGF/Cr 水平较高(>21.45ng/mg)可作为蛋白尿 CR 的独立预测因子。基线 uEGF/Cr 联合传统临床病理参数可显著提高预测蛋白尿 CR 的拟合能力。uEGF/Cr 的纵向数据也与蛋白尿 CR 独立相关。本研究表明,尿 EGF 可能是预测蛋白尿 CR 以及监测治疗反应的有用非侵入性生物标志物,从而为 IgAN 患儿的临床实践提供治疗策略指导。